ADROVANCE

Brand name authorized in: Austria Spain France Ireland Italy Lithuania Netherlands Poland

Active ingredients

The drug ADROVANCE contains a combination of these active pharmaceutical ingredients (APIs):

1 Alendronic acid
UNII 2UY4M2U3RA - ALENDRONATE SODIUM

Alendronic acid is a bisphosphonate that inhibits osteoclastic bone resorption with no direct effect on bone formation. The bone formed during treatment with alendronic acid is of normal quality.

Read about Alendronic acid
2 Vitamin D3
UNII 1C6V77QF41 - CHOLECALCIFEROL

In its biologically active form vitamin D3 stimulates intestinal calcium absorption, incorporation of calcium into the osteoid, and release of calcium from bone tissue. In the small intestine it promotes rapid and delayed calcium uptake. The passive and active transport of phosphate is also stimulated.

Read about Vitamin D3

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code
Group title
Classification
Alendronic acid and colecalciferol
M Musculo-skeletal system → M05 Drugs for treatment of bone diseases → M05B Drugs affecting bone structure and mineralization → M05BB Bisphosphonates, combinations
Discover more medicines within M05BB03

Unique identifiers

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country
Identification scheme
Identifier(s)
ES
Centro de información online de medicamentos de la AEMPS
Identifier(s): 06364002, 06364007
FR
Base de données publique des médicaments
Identifier(s): 63230395, 63725282
IT
Agenzia Italiana del Farmaco
Identifier(s): 037603026, 037603077
LT
Valstybinė vaistų kontrolės tarnyba
Identifier(s): 1026343, 1026344, 1026345, 1026346, 1061952, 1061953, 1061954
NL
Z-Index G-Standaard, PRK
Identifier(s): 122424, 122432
PL
Rejestru Produktów Leczniczych
Identifier(s): 100308545, 100308551